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Heart failure is a serious cause of morbidity and mortality with many patients
ultimately requiring heart transplantation. As the rate of heart failure continues to
increase and surpass the number of available donor hearts, the need for cardiac
assist devices is rapidly rising. The total artificial heart has emerged as an effective
therapeutic option in patients with end-stage biventricular heart failure who are
awaiting orthotopic heart transplantation. The TAH replaces the patient’s native
ventricle and valves and has one of the highest bridge to transplant rates. Many
complications have been associated with the TAH including infections, bleeding,
thrombosis, device malfunction, neurological complications among others. CT is
the imaging modality of choice that aids in early recognition of TAH complications.
The aim of this review is to illustrate the TAH components and CT based imaging
of TAH complications. Recognition of TAH complications can help to plan for early
intervention and therefore improve patient’s survival.
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Introduction
Heart failure is recognized as a major health problem [1-3]. According to the
American Heart Association (AHA), there are approximately 5.8 million of
Americans with heart failure and 500,000 new cases of heart failure are diagnosed
each year [1, 2]. The prognosis of heart failure is poor with estimates rates of
survival of 50% at 5 years and 10% at 10 years [4]. Orthotropic heart
transplantation has been the definitive form of therapy for patients with end-stage
biventricular heart failure. However, only 2200 donor hearts are available each
year [5]. This discrepancy between the clinical need for donor hearts and the
available supply has led to the development of devices such as the total artificial
heart (TAH) [1-3, 5, 6].
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The Jarvik 7 was the first attempt to artificial implantable hearts, but the recipients
suffered major complications [7]. The Abiocor TAH was first implanted in humans
in 2001 in a destination therapy trial of fourteen patients who received this device
but none of the patients survived in this trial. The Abiocor device has been
unavailable since then [6].
The Syncardia total artificial heart (TAH), formerly CardioWest, is the only
implantable device approved by the United States Food and Drug Administration
(FDA) for patients with severe biventricular heart failure [5-12]. Flow rates in the
Syncardia device are normally 7-9L/min and there is very little turbulence within
the device [13].
The goal of the total artificial heart is to bridge patients to heart transplantation,
replace failing ventricles, malfunctioning valves and eliminate arrhythmias [5-16].
Other mechanical circulatory assist devices include short-term cardiac assist
devices such as the Tandem-Heart percutaneous assist device (Cardiac Assist)
and the Impella [7,17]. The Tandem-Heart is an extracorporeal continuous flow
centrifugal assist device used to treat postcardiotomy shock and as to bridge to
heart transplantation [7,17]. The Impella device is used as a minimally invasive
option for patients requiring temporary cardiac support for acute heart failure,
cardiogenic shock or patients undergoing high risk percutaneous interventions to
avoid hemodynamic instability [18].
One of the mainstays for mechanical support for patients with end-stage
ventricular failure are the ventricular assist devices (VADs). These can be used to
assist in the function of a single ventricle (RVADs: right ventricular assist devices,
LVADs: Left ventricular assist devices) or in biventricular failure (BiVAD:
biventricular assist devices) [17-19].
The LVADs are used as bridge to heart transplantation, as a bridge to myocardial
recovery and as destination therapy in patients who are not candidates for heart
transplant. There are two main categories of LVADs : earlier generation or
pulsatile flow devices (HeartMateXVE) and late generation or continuous flow
devices (Jarvik 2000, VentrAssist, HeartMate II, Heartware and HeartMate III) [1820]. Continuous devices provide an advantage to their first generation counterpart
including smaller size, less noise and increased durability and reliability (Table 1)
[18].
Of all these devices, the total artificial heart (Syncardia) has one of the highest
bridge to transplant rate. It is reported that 79% of patients with the Syncardia TAH
survive to orthotopic heart transplant [5,11,13]. In a study conducted by Copeland
et al. survival after Syncardia transplantation at 1, 5 and 10 years was reported to
be 76.8%, 60.5% and 41.2% respectively [21].
There have been more than 1250 implants of the total artificial heart accounting for
more than 350 patient-years of life with this device [5].
Torregrossa et al. have described the use of Syncardia TAH as a destination
therapy in patients not eligible for heart transplantation [16].
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Table 1: First and second generation left ventricular assist devices (LVADs)

Total Artificial Heart Indications and Contraindications
Candidates for total artificial heart are those with end-stage biventricular heart
failure (New York Association functional class IV) who are eligible to receive
orthotopic heart transplant. The body surface area must be at least 1.7m2 and the
distance between the posterior cortex of the sternum and anterior cortex of T10
vertebra should be at least
10cm (Figure 1) in order to
accommodate the device
[5,12,13].Contraindications to
TAH include transplant
inedibility, left heart failure in
absence of right-heart failure,
high risk for anticoagulation,
and a small thoracic cavity
unsuitable to fit the device
[5,12,13]. Other exclusion
criteria are: concomitant use of
another vascular assist device
and pulmonary vascular
resistance of equal or greater
than 8 Wood units [13].
Figure 1.The distance
between the posterior cortex of the sternum and the anterior cortex of T10
should be at least 10 cm to accommodate the TAH.
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Total Artificial Heart Components
The TAH consists of two artificial ventricles and four mechanical valves: two 27
mm inflow valves (atrioventricular valves) and two 25 mm outflow valves (aortic
and pulmonic valves).
Each of the two artificial ventricles (right and left) house four flexible polyurethane
diaphragms including a seamless blood contacting diaphragm, two intermediate
diaphragms and an air diaphragm [5,6,12].
The artificial left ventricle is connected to the native left atrium by a left atrial
flexible polyurethane inflow connector (Quickconnect) and to the native aorta by an
aortic outflow cannula. Similarly, the artificial right ventricle is connected to the
native right atrium by a right atrial flexible polyurethane inflow connector
(Quickconnect) and to the native pulmonary aorta by a pulmonary artery outflow
cannula (Figure 2) [5,6,12]. The two artificial ventricles housing flexible
polyurethane diaphragms are connected to two pneumatic drivelines. This design
allows the ventricles to fill and then eject blood when compressed by air from an
external console [5,12].
There are two types of console: a standard bedside console (Big Blue) and a
portable driver system (Freedom Driver) [5]. The console provides monitoring of
data such as device rate, stroke volume and cardiac output as well as patientrelated alarms. Each artificial ventricle of the TAH delivers a maximum stroke
volume of 70mL [5,6].

Figure 2. Syncardia
TAH components.

Total Artificial Heart
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Implantation
The native ventricles, ventral surface of the atria, the proximal ascending aorta and
pulmonary artery are surgically removed. Inflow right and left atrial connectors are
attached to the native atrial remnants. Likewise, aortic and pulmonic outflow
connectors are anastomosed with the native thoracic aorta and pulmonary artery.
The artificial ventricles and pneumatic drivelines are then installed (Figure 3)
[5,12].
The native pericardial sac is left open and the TAH implant is enfolded
polytetrafluoroethylene that functions as neopericardium which favors future
explantation. A tissue expander (Mentor walled silicone filled with saline) is placed
between the artificial and left ventricle to avoid contraction of the surgical cavity
and to facilitate explantation for orthotopic heart transplant [5].

Figure 3. Steps for total artificial heart implantation. A. Failing heart endstage biventricular failure. B. Both failing native ventricles are surgically
removed. C. Excision of the atrioventricular, pulmonic and aortic valves. D.
Complete removal of the ventricular chambers, ventral atria and proximal
pulmonary and aorta. E. Right and left atrial inflow connectors
(Quickconnect) and outflow pulmonary and aortic conduits are inserted. F.
The two artificial ventricles with pneumatic drivelines are implanted.
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Total Artificial Heart Imaging Modalities
Chest radiograph is utilized after TAH implantation to monitor the device and to
evaluate for potential complications. The TAH mechanical valves are not situated
in their expected anatomic location on a plain chest radiograph. Moreover, the airfilled ventricles seen in systole (diaphragm move inwards to empty the ventricles)
can be mistaken with mediastinal air collections creating potential diagnostic errors
of interpretation [5].
Echocardiogram, in particular transesophageal echocardiography (TEE) can be
used pre-operatively and intraoperatively to establish a baseline to identify future
valve malfunctions [22]. However, some of the limitation of TEE is the challenging
evaluation of the aortic valves due to poor transgastric windows and acoustic
shadowing of the device. Also, reverberation and ring artifacts generated from the
TAH mechanical valves can also hinder imaging of the ventricular chambers [22].
CT is the modality of choice to assess the TAH (Figure 4) [5]. Contrast can be
administered in patients who can tolerate the contrast media and those with
adequate renal function. For patients who cannot receive contrast, an
unenhanced CT can be performed [5]. Prospective or retrospective cardiac gating
is not feasible given that there is no recordable ECG (no QRS complex) [5]. MRI is
contraindicated due to unsafety which precludes MRI evaluation (Table 2).

Figure 4. Axial NCCT (A), coronal NCCT
(B), and Chest radiograph (C) showing
TAH parts: TV=artificial Tricuspid
valve; MV=artificial mitral valve;
RV=artificial right ventricle,
AV=artificial aortic valve; PV=
artificially pulmonic valve partially
seen; LV=artificial left ventricle; PGC=
pulmonary graft conduit not well seen;
AGC=Aortic graft conduit; LVPD: left
ventricle pneumatic driveline; RVPD:
right ventricle pneumatic driveline; N=
neopericardium; TE=tissue expander.
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Table 2. Imaging modalities of the TAH.
Therefore, it is important to become familiar with the normal CT appearance of the
TAH and its components as well as to recognize its complications.

Total Artificial Heart Complications:
TAH Infectious complications
Infectious complications are one of the most common adverse events in TAH
recipients (53-62%) and may involve the mediastinum, pericardium, driveline and
respiratory tract (Figures 5-11) [5,14,16].
Torregrossa et al. reported driveline infections in 27 % of patients [16] and
Copeland described postoperative infections in 77% of patients [14].
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Figure 5. Infectious complications;
Mediastinal abscess. A) Axial; B) coronal
and C) sagittal NCCT show fluid collection
in the anterior mediastinum (thick arrow)
with flecks of air (thin arrow) indicating
abscess. D) Axial and E) NCCT portray
fluid collection in the anterior
mediastinum (thick arrow) in a different
patient.
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Figure 6. Infectious complications; neopericardium/ intra-cardiac infection.
A) Axial and B) coronal NCCT depict mediastinal collection (dashed thin
arrow) with associated disruption of the neo-pericardium (thick arrow) and
flecks of air (short arrow) caused by pericardial bacterial infection. C) Illdefined hyperdensity in the neopericardial fluid (thick arrow) proven to be
fungal infection.
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Figure 7 Infectious complications;
superficial and retrosternal abscess. A)
Axial and B) Axial NCCT depicts infiltrative
changes overlying the sternotomy wires
(thick arrow). C) Axial NCCT performed 2
weeks later shows a fluid collection
superficial to the sternotomy wires (short
arrow) and in the retrosternal space (dashed
arrow) in the same patient consistent with
abscess.

Figure 8. Infectious complications; infected pericardial fluid. A) Axial and B)
coronal NCCT demonstrates a fluid collection (thick arrow) around the
neopericardium proven to be infected.
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Figure 9. Infectious complication involving the pneumatic drivelines. A) Axial
B) Axial and C) coronal NCCT depicts fluid collection (thick arrow) and
stranding (thin dashed arrow) around the pneumatic drivelines with
extension into the preperitoneal space (short arrow).
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Figure 10. Infectious complications; multifocal pneumonia. A) Axial and B)
sagittal NCCT depicts patchy ground-glass opacities (dashed orange
arrows) and pleural effusions (short arrow) in this patient with multifocal
pneumonia. C) Axial NCCT shows patchy airspace opacities bilaterally
(dashed yellow arrows) representing multifocal pneumonia. Also, there are
associated diffuse ground-glass opacities (asterisk) consistent with
overlying pulmonary edema.
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Figure 11. Infectious complications; septic emboli. A) Axial and B) sagittal
NCCT portrays nodular opacities (thick arrow) in the bilateral lungs
consistent with septic emboli. C) Coronal NCCT shows feeding vessel sign
(dashed arrow) in the same patient consistent with hematogeneous spread
of infection.

TAH Hematoma/Bleeding
Postoperative bleeding occurred in 23% and 62% of TAH recipients in the studies
conducted by Parker et. al and Copeland et.al respectively. The most common
sites of bleeding are the mediastinum (hemomediastinum) and thorax
(hemothorax) (Figures 12-16) [5,14]. Localized right atrial tamponade has been
described [5,12]. Leprince et al. reported two cases in their study of 127 patients
[23].
The use of anticoagulation can predispose to delayed extrathoracic hemorrhage
including subarachnoid and retroperitoneal hemorrhage [24].
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Figure 12 TAH mediastinal hematoma.
A) Axial, B) axial and C) coronal NCCT shows an anterior mediastinal hematoma
(thick arrow) which compresses and causes deformity of the right cardiac
chambers, predominantly of the right atrium (dashed arrow). D) Axial NCCT
shows evacuation of hematoma. E) Small mediastinal hematoma (thick arrow) in
a different patient with focus of suture dehiscence (short arrow).
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Figure 13. Hematoma around the pneumatic drivelines. A) Axial, B) axial ,C)
coronal and D) sagittal NCCT depicts high density fluid surrounding the
pneumatic drivelines (thick arrow) representing hematoma.
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Figure 14. TAH
Hemopericardium. A) Axial and
B) coronal NCCT depicts high
density fluid representing
hemopericardium (thick arrow)
with mass effect on the left
cardiac chambers. C) NCCT
shows suture line dehiscence
in the right atrial chamber (thin
arrow) which was repaired
surgically.
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Figure 15. Retroperitoneal hematoma. A) Axial and B) coronal NCCT shows
heterogeneous high density collection in the retroperitoneum (thick arrow)
representing hematoma.

Figure 16 Pulmonary hemorrhages. A) Chest radiograph shows diffuse
alveolar opacities (thin dashed arrow). B, C) Axial and coronal NCCT depicts
confluent areas of consolidation and diffuse alveolar opacities (thick
arrows)in the bilateral lungs proven to be pulmonary hemorrhage.
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TAH Thrombosis/Infarct
The TAH has been associated with significant risk of thrombosis including the lung
and solid organs (e.g. spleen, kidney) (Figures 17 and 18). Parker et al. reported
4.5 % cases of acute pulmonary embolism in TAH recipients [5]. Torregrossa et al.
reported 19% of thromboembolic events in recipients 1 year post-implantation [16].
In patients with TAH, optimal anticoagulation includes both anticoagulant such as
warfarin and antiplatelet therapy.

Figure 17. Pulmonary embolism/infarction. A) Axial contrast enhanced CT
(CECT) shows pulmonary embolism (thick arrow) in the right main
pulmonary artery extending into the interlobar artery. B) Coronal CECT
shows wedge shape area of hyperattenuation in the right lung consistent
with pulmonary infarct (dashed arrow).

Figure 18 Solid organ infarcts. A. CECT depicts large splenic infarct (thick
arrow). B. CECT portrays infarct in the right kidney (thick arrow).
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TAH Device Malfunction
The surgical anastomosis between the device components including the great
vessels and synthetic inflow atrial connectors and great vessel outflow connectors
may become weak and break down. Surgical dehiscence require immediate repair.
Other commonly encountered complication occurring with the drivelines are kinks
and leaks [5].

TAH Neurologic Complications
Leprince et al. reported a low stroke rate in TAH recipient (0.2 events per patient
per year) [23]. Kirsch et al. have reported 10% cases of stroke in a study
conducted in 90 patients [25]. Subarachnoid hemorrhage also occurs in patient
with TAH and is related to anticoagulation therapy (Figure 19) [5].

Figure 19. TAH neurologic complications. A) Non contrast head CT shows
infarct in the left MCA territory (thick arrow). B) Non contrast CT shows
subarachnoid hemorrhage (thin arrow) in the bilateral cerebral convexities.
Other complications seen with the TAH can be due to hypoperfusion and include
mesenteric ischemia and bowel perforation (Figure 20).
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Figure 20 Bowel ischemia A) Abdominal radiograph portrays distension of
small bowel loops (dashed arrow). B) CECT depicts bowel wall thickening
(thick arrow), mesenteric stranding (thin arrow) and pneumatosis (thin
dashed arrow) consistent with bowel ischemia. C) CECT in the same patient
shows air in the superior mesenteric vein and its branches (short arrow). D)
Sagittal CECT shows pneumatosis (thin dashed arrow), bowel wall
thickening (thick arrow) and gas in the SMV and portal vein (short arrows)
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Overload states (Figure 21) such as ascites, anasarca, pulmonary edema and
effusions have also been described.

Figure 21 Ascites, anasarca. A) Axial B) axial and C) coronal NCCT shows
fluid in the paracolic gutters and pelvic cavity (thick arrows) as well as
subcutaneous edema (thin arrow) representing anasarca.
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Conclusions
The Syncardia total artificial heart (TAH) is the only implantable device approved
by the United States Food and Drug administration (FDA) for use in patients
suffering from biventricular heart failure. It is a device used in patients with endstage biventricular heart failure while waiting for orthotopic heart transplantation.
The most common complications on TAH recipients include infections, bleeding,
thrombosis, liver failure, renal failure, and neurological events such as stroke and
device malfunction. Infectious and hemorrhagic complications have been reported
as major causes of death [5].
The role of CT imaging in the recognition of clinical outcomes associated with TAH
complications is of paramount importance to guide clinicians in early therapeutic
interventions to improve patient’s survival ultimately yield longer survival times.
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